Oct 08 2024

Montana: Licensed Marijuana Stores Sold $27 Million Worth of Product in September

Legal marijuana sales in Montana topped $27 million in September.

According to data released by the Montana Department of Revenue, total marijuana sales reached $27,520,406 in September. This is a slight dip from the record-breaking $29,716,881 sold in August, and is on par with the $28 million sold in September 2023.

The vast majority of the state’s total marijuana sales was purchased for recreational use, $23,965,392, with medical marijuana patients purchasing $3,555,014 worth of product. Sales data incudes dried marijuana flower, prerolls and concentrates, as well as a variety of marijuana-infused products like edibles, topicals and tinctures.
Continue reading

Oct 08 2024

Delaware Receives Over 1,200 Applications for Marijuana Business Licenses, Including 800 for Retail Outlets

Delaware has received over 1,260 applications between August 19 and September 30, according to data released by the state.

(Photo credit: Getty Images).

Of these, 800 applications were for the 30 available retail licenses, according to Delaware’s Office of the Marijuana Commissioner. The state generated over $4 million from application fees.

Applicants paid $5,000 for an open application (non-social equity or microbusiness), $3,000 for a microbusiness license, and $1,000 for a social equity license.
Continue reading

Oct 08 2024

Cannabis Nanoemulsion Shows Breakthrough Potential in Glioblastoma Treatment, Dramatically Extending Survival in Animal Study

A new study published in the journal BMC Pharmacology and Toxicology reveals a promising advancement in glioblastoma treatment using a nanoemulsion containing cannabis extract.

Researchers from the University of Medical Sciences, University of Tehran, and North Khorasan University of Medical Sciences in Iran have developed a nanoemulsion designed to boost the effectiveness of two key cannabis compounds, THC and CBD, in treating this aggressive form of brain cancer. The study demonstrated that this innovative delivery method significantly reduced tumor size and extended survival in animal models, potentially offering a new therapeutic avenue for glioblastoma.

The researchers aimed to enhance the delivery of ∆9-Tetrahydrocannabinol (THC) and Cannabidiol (CBD) through a nanoemulsion (NE), allowing for better absorption and effectiveness of the drugs. In their in vitro and in vivo studies, they compared the efficacy of the cannabis-loaded nanoemulsion (NED) to standard drug delivery methods and a control group using the C6 tumor model in rats.
Continue reading

Oct 08 2024

New Jersey Senate Committee Passes Bill Banning Electronic Smoking Device Deliveries to Those Under 21

On October 7, New Jersey’s Assembly Bill 1813 was given approval by the Senate Health, Human Services, and Senior Citizens Committee.

The bill, which was passed overwhelmingly by the Assembly on September 26 with a vote of 73-2, seeks to tighten regulations on the delivery of electronic smoking devices, ensuring they do not reach individuals under 21 years of age.

The proposed legislation specifically prohibits the delivery of electronic smoking devices or tobacco products to any residence without first securing the signature of a person at least 21 years old. Violators of this law would face the same civil and criminal penalties already in place for those who sell or supply tobacco products and electronic smoking devices to underage individuals.
Continue reading

Oct 07 2024

New Jersey: Second Senate Committee Approves Measure to Legalize Psilocybin for Therapeutic Use

A second committee in the New Jersey Senate has voted to pass legislation to legalize the therapeutic use of psilocybin mushrooms.

Psilocybin mushroom.

The Senate Senate Budget and Appropriations Committee has given approval to Senate Bill 2283, roughly four months after it was passed by the Senate’s Health, Human Services, and Senior Citizens Committee.

Sponsored by Senate President Nick Scutari (D), the bill initially would have allowed individuals 21 and older to “possess, store, use, ingest, inhale, process, transport, deliver without consideration, or distribute without consideration, four grams or less of psilocybin.” However, it was amended before passage to focus on the therapeutic use of psilocybin for those with a qualifying medical condition.
Continue reading

Oct 07 2024

North Carolina Marijuana Superstore Celebrates One Month Open to Everyone 21+

The Great Smoky Cannabis Company in Cherokee, North Carolina, has now been open for exactly one month, with tens of thousands of patrons making purchases.

The Great Smoky Cannabis Company (91 Bingo Loop Rd, Cherokee), located on the tribal land of Eastern Band of Cherokee Indians, has been open to everyone 21 and older since September 7. Today, they celebrate a full month of being open. During that time, the store has had over 20,000 customers, with not a single arrest reported by patrons leaving tribal land after making a purchase.

The Great Smoky Cannabis Company has been referred to by many as a “superstore” or “megastore”, given it is one of the largest marijuana stores in the United States. It’s the home of a former bingo hall that cost $50 million to renovate. The store first opened on April 20, but was only accessible by tribal members.
Continue reading

Oct 07 2024

These Five Marijuana Strains are the Most Popular As of October 2024

As the cannabis market continues to expand across the U.S., several strains have captured the attention of consumers.

Runtz.

Using data from various state regulatory agencies, as well as data from sites that track strain popularity such as Leafly, here are the five marijuana strains dominating sales as of October 2024. Continue reading

Oct 07 2024

Maine Sees $21 Million in Marijuana Sales During September, Surpassing 400,000 Transactions

Maine’s marijuana market continues to demonstrate resilience, with September reporting a total of $21,275,491 in sales across 407,240 transactions.

Within these sales, $12.5 million was attributed to “usable cannabis,” $5.6 million to marijuana concentrates, and $3.1 million to “infused products.”

With September’s sales, the year-to-date total has reached an impressive $183,209,598 from 3,406,206 transactions, according to the Maine Office of Cannabis Policy.
Continue reading

Oct 07 2024

Report: CBD Skincare Market Valued at $2.3 Billion, Projected to Reach $22 Billion by 2032

According to a newly released report, the global market for CBD skin care products is valued at over $2 billion, and is expected to grow at a drastic rate over the next eight years.

The SNS Insider report indicates that the market is valued at $2.29 billion in 2023, and is projected to reach $22 billion by 2032 with a remarkable CAGR (compound annual growth rate) of 28.7% over the forecast period from 2024 to 2032.”

“The CBD skincare product market is very promising and growing with the fact that people today are desperately looking for natural and organic ingredients in personal care products”, states the report. “Consumers prefer products that offer therapeutic benefits without chemicals that can have adverse impacts.”
Continue reading

Oct 07 2024

Study: Medical Marijuana Dosing Patterns Vary Widely by Condition, Finds Analysis of Over 16,000 Patients

According to a study published recently in the journal Clinical Therapeutics, there is significant variations in medical marijuana use based on patients’ medical conditions.

Researchers from the University of Southern California, Brandeis University, and Monash University in Australia analyzed data from over 16,000 patients who purchased medical cannabis from dispensaries in New York over a four year period. The study sought to better understand patterns in the consumption of Δ-9-tetrahydrocannabinol (THC) and cannabidiol (CBD) over time.

Using purchase data recorded in point-of-sale systems, the researchers identified six distinct patterns of cannabis dosing. For THC, the majority of patients (62.6%) maintained steady doses at either low (4.1 mg) or moderate levels (7.4 mg). Approximately 22% of patients exhibited fluctuating or increasing THC doses over time, ranging from 5 to 20 mg. A smaller group, making up 15.8% of the total, decreased their THC intake from 11 mg to 5 mg over the study period. Similar patterns were observed for CBD, though the dosing levels tended to be higher, ranging between 4 and 16 mg.
Continue reading